Sign Up to like & get
recommendations!
0
Published in 2020 at "Hematology/oncology and stem cell therapy"
DOI: 10.1016/j.hemonc.2020.10.003
Abstract: OBJECTIVE/BACKGROUND B-cell neoplasms are clonal tumors of B cells at various stages of maturation, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic lymphoma (CLL), Burkitt lymphoma (BL), lymphoplasmacytic lymphoma (LPL)/Waldenström's macroglobulinemia (WM), splenic marginal zone…
read more here.
Keywords:
lymphoma;
l265p mutation;
myd88 l265p;
cell ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "Ocular Immunology and Inflammation"
DOI: 10.1080/09273948.2020.1802488
Abstract: ABSTRACT Purpose To report a case of a patient whose MYD88 mutation disappeared from the aqueous humor following treatment with intravitreal methotrexate. Methods A retrospective review of clinical, histopathological and imaging records. Results A 49-year-old…
read more here.
Keywords:
myd88 l265p;
l265p mutation;
mutation;
vitreoretinal lymphoma ... See more keywords
Sign Up to like & get
recommendations!
4
Published in 2023 at "Cancer Science"
DOI: 10.1111/cas.15762
Abstract: The myeloid differentiation primary response gene 88 (MYD88) L265P mutation is a disease‐specific mutation of primary central nervous system lymphoma (PCNSL) among the central nervous system tumors. Accordingly, this mutation is considered a reliable diagnostic…
read more here.
Keywords:
detection myd88;
myd88 l265p;
myd88;
l265p mutation ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "PLoS ONE"
DOI: 10.1371/journal.pone.0221941
Abstract: We investigated the feasibility of using next-generation sequencing (NGS) technique using molecular barcoding technology to detect MYD88 L265P mutation in unselected peripheral blood mononuclear cells (PBMCs) in 52 patients with Waldenström’s macroglobulinemia [1] and 21…
read more here.
Keywords:
peripheral blood;
myd88 l265p;
l265p mutation;
next generation ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "Oncology Letters"
DOI: 10.3892/ol.2017.7472
Abstract: The aim of this study was to analyze the prevalence and prognostic value of myeloid differentiation factor 88 (MYD88) L265P in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and…
read more here.
Keywords:
prognostic value;
myd88 l265p;
l265p mutation;
myd88 ... See more keywords